english.prescrire.org > Prescrire International > N°224 - March 2021

n°224

March 2021

Issue Contents
Editorial

Free  Doing one's job

p.59

New Products


Romosozumab (Evenity°) and severe postmenopausal osteoporosis

p.61-64
Possible increase in mortality and cardiovascular events, with an efficacy barely superior to alendronic acid

INN Common stem: -domide

p.64

Free  Polatuzumab vedotin (Polivy°) and large B-cell lymphoma

p.65

Treosulfan (Trecondi°) and preparation for haemo­poietic stem cell transplantation

p.66-67

Upadacitinib (Rinvoq°) and rheumatoid arthritis

p.67-68

Adverse Effects


Fingolimod: measures to prevent its teratogenic effect

p.69

Nalmefene + opioids: withdrawal syndromes

p.69-70

DPD deficiency testing recommended in the European Union before cancer treatment with a fluoropyrimidine

p.70

Hand sanitiser dispensers and young children: accidental eye splashing

p.71

Baricitinib: diverticulitis and gastrointestinal perforation

p.71

Ginkgo biloba: cardiac rhythm disorders?

p.72

Drug-induced dry eye

p.72

Reviews


Covid-19: a recap of treatment options

p.73-75
From Prescrire's comprehensive year-end review

Atopic eczema

p.75-76
Continue to avoid tacrolimus and pimecrolimus

Outlook


Free  2020 Prescrire Drug Awards

p.77-78

Free  The Prescrire Awards for 2020

p.77-81

Free  2020 Prescrire Packaging Awards

p.79-80

Free  2020 Information Awards

p.81

Novartis: a large-scale bribery scheme

p.82

Comparative trials: an ethical issue

p.82-83

Generic drug company prosecuted for ­incomplete description of risks in a patient information leaflet

p.83

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe